Search This Blog

Tuesday, May 14, 2024

Arcutis Biotherapeutics Stock Climbs After Blockbuster Q1

 

  • Arcutis reports quarterly earnings of 32 cents per share which beat the analyst consensus estimate of losses of 73 cents.
  • Quarterly sales clock in at $49.57 million, beating the analyst consensus estimate of $14.68 million by 237.66%.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)